CRISPR Therapeutics
Leading gene-editing company developing CRISPR/Cas9-based therapeutics, including Casgevy (exagamglogene autotemcel), the first FDA-approved CRISPR gene therapy for sickle cell disease and beta-thalassemia.
Notes
CRISPR Therapeutics (NASDAQ: CRSP) is a pioneering gene-editing company focused on developing transformative gene-based medicines using the CRISPR/Cas9 technology. Co-founded by Emmanuelle Charpentier (2020 Nobel Prize in Chemistry recipient), the company is a global leader in the development of CRISPR-based therapeutics.
In December 2023, the company achieved a historic milestone when Casgevy (exagamglogene autotemcel), developed in partnership with Vertex Pharmaceuticals, became the first CRISPR-based gene therapy to receive FDA approval. Casgevy is approved for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia.
Team
- Samarth Kulkarni, Ph.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/samarthkulkarni
- Emmanuelle Charpentier, Ph.D. - Co-founder (2020 Nobel Prize in Chemistry)
- Phuong Khanh Morrow, M.D. - Chief Medical Officer
- James R. Kasinger - Chief Financial Officer
Additional Research Findings
- NASDAQ: CRSP (publicly traded)
- Co-founded by Nobel Laureate Emmanuelle Charpentier
- Casgevy (exagamglogene autotemcel): first FDA-approved CRISPR therapy
- FDA approval December 2023 for sickle cell disease and beta-thalassemia
- Partnership with Vertex Pharmaceuticals
- Pipeline includes programs in immuno-oncology, regenerative medicine
- Dual headquarters: Zug, Switzerland and Boston, Massachusetts
- CAR-T cell therapy programs using CRISPR editing
- Pioneering allogeneic (off-the-shelf) CAR-T therapies
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Vertex Pharmaceuticals | Boston, Massachusetts, USA | cvc | series-aseries-b+2 | 1 |